SEC Form 4 · accession 0002043558-26-000005
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jayson Rieger
Officer — CEO and President · Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 18, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001660334
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 14, 2026 | P | 20,000 | $5.06 | A | 202,593 | D | |
| Common Stock | Aug 17, 2026 | P | 5,000 | $4.91 | A | 207,593 | D | |
| Common Stock | holding | — | — | — | 15 | I | By child | |
| Common StockF2 | holding | — | — | — | 230 | I | By trust | |
| Common StockF2 | holding | — | — | — | 230 | I | By trust | |
| Common StockF2 | holding | — | — | — | 230 | I | By trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.